What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: Allied Market Research | PRODUCT CODE: 1566964

PUBLISHER: Allied Market Research | PRODUCT CODE: 1566964

Atorvastatin Calcium Market By Form , By Application By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

PUBLISHED: July 10, 2024

PAGES: 280 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected to reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.

Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.

The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60-79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.

The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023, and is is expected to dominate from 2024 to 2033.

By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.

Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Form

Tablets
Others

By Application

Hypercholesterolemia
Hyperlipidemia
Others

By Distribution Channel

Hospital pharmacies
Drug store retail pharmacies
Online providers.

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Mylan Pharmaceuticals Inc.
Novartis AG
GlaxoSmithKline plc
Amgen Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd
Merck and Co. Inc.
Bristol-Myers Squibb Company
AstraZeneca Plc
Pfizer Inc.

Product Code: A324370

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: ATORVASTATIN CALCIUM MARKET, BY FORM

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Form
4.2. Tablets
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Others
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ATORVASTATIN CALCIUM MARKET, BY APPLICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
5.2. Hypercholesterolemia
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Hyperlipidemia
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Others
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Drug Store Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Online Providers.
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ATORVASTATIN CALCIUM MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Form
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Atorvastatin Calcium Market
  - 7.2.6.1. Market Size and Forecast, By Form
  - 7.2.6.2. Market Size and Forecast, By Application
  - 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Atorvastatin Calcium Market
  - 7.2.7.1. Market Size and Forecast, By Form
  - 7.2.7.2. Market Size and Forecast, By Application
  - 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Atorvastatin Calcium Market
  - 7.2.8.1. Market Size and Forecast, By Form
  - 7.2.8.2. Market Size and Forecast, By Application
  - 7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Form
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Atorvastatin Calcium Market
  - 7.3.6.1. Market Size and Forecast, By Form
  - 7.3.6.2. Market Size and Forecast, By Application
  - 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Atorvastatin Calcium Market
  - 7.3.7.1. Market Size and Forecast, By Form
  - 7.3.7.2. Market Size and Forecast, By Application
  - 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Atorvastatin Calcium Market
  - 7.3.8.1. Market Size and Forecast, By Form
  - 7.3.8.2. Market Size and Forecast, By Application
  - 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Atorvastatin Calcium Market
  - 7.3.9.1. Market Size and Forecast, By Form
  - 7.3.9.2. Market Size and Forecast, By Application
  - 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Atorvastatin Calcium Market
  - 7.3.10.1. Market Size and Forecast, By Form
  - 7.3.10.2. Market Size and Forecast, By Application
  - 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest of Europe Atorvastatin Calcium Market
  - 7.3.11.1. Market Size and Forecast, By Form
  - 7.3.11.2. Market Size and Forecast, By Application
  - 7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Form
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Atorvastatin Calcium Market
  - 7.4.6.1. Market Size and Forecast, By Form
  - 7.4.6.2. Market Size and Forecast, By Application
  - 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Atorvastatin Calcium Market
  - 7.4.7.1. Market Size and Forecast, By Form
  - 7.4.7.2. Market Size and Forecast, By Application
  - 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Atorvastatin Calcium Market
  - 7.4.8.1. Market Size and Forecast, By Form
  - 7.4.8.2. Market Size and Forecast, By Application
  - 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Atorvastatin Calcium Market
  - 7.4.9.1. Market Size and Forecast, By Form
  - 7.4.9.2. Market Size and Forecast, By Application
  - 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Atorvastatin Calcium Market
  - 7.4.10.1. Market Size and Forecast, By Form
  - 7.4.10.2. Market Size and Forecast, By Application
  - 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Atorvastatin Calcium Market
  - 7.4.11.1. Market Size and Forecast, By Form
  - 7.4.11.2. Market Size and Forecast, By Application
  - 7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Form
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Atorvastatin Calcium Market
  - 7.5.6.1. Market Size and Forecast, By Form
  - 7.5.6.2. Market Size and Forecast, By Application
  - 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Atorvastatin Calcium Market
  - 7.5.7.1. Market Size and Forecast, By Form
  - 7.5.7.2. Market Size and Forecast, By Application
  - 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Atorvastatin Calcium Market
  - 7.5.8.1. Market Size and Forecast, By Form
  - 7.5.8.2. Market Size and Forecast, By Application
  - 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Atorvastatin Calcium Market
  - 7.5.9.1. Market Size and Forecast, By Form
  - 7.5.9.2. Market Size and Forecast, By Application
  - 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Mylan Pharmaceuticals Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Novartis AG
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. GlaxoSmithKline Plc
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Amgen Inc.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Sanofi SA
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Teva Pharmaceuticals Industries Ltd
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Merck And Co. Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Bristol-Myers Squibb Company
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. AstraZeneca Plc
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments